# APC mutation associated with familial colorectal cancer in Ashkenazi jews

**Publication number:** DE69814622T
**Publication date:** 2004-02-26
**Inventor:** LAKEN STEVE (US); GRUBER STEPHEN (US); PETERSEN GLORIA (US); KINZLER KENNETH (US); VOGELSTEIN BERT (US)
**Applicant:** UNIV JOHNS HOPKINS (US)
**Classification:**
**- international:** ***C12Q1/68; G01N33/574;*** **C12Q1/68; G01N33/574;** (IPC1-7): C12Q1/68; G01N33/574
**- european:** C12Q1/68M6B; G01N33/574; G01N33/574C6
**Application number:** DE19986014622T 19980121
**Priority number(s):** US19970791883 19970131; WO1998US00961 19980121

**Also published as:**
WO9833940 (A1)
EP0981644 (A1)
US5879890 (A1)
EP0981644 (A0)
CA2278781 (A1)
more >>

Report a data error here

Abstract not available for DE69814622T
Abstract of corresponding document: **US5879890**

During routine screening of a patient with a family history of colorectal cancer for truncating APC mutations, a novel missense mutation was identified. Upon further evaluation, it was found that 6% of Ashkenazi Jews carry this mutation, and that it was present in DIFFERENCE 20% of Ashkenazis with a family history of CRC. Probes, methods, and kits for identifying individuals affected with this missense mutation are provided.

# Characterising and identifying disseminated metastatic cancer cells

**Publication number:** DE19736691
**Publication date:** 1999-02-25
**Inventor:** GIESING MICHAEL PROF DR MED (DE)
**Applicant:** GIESING MICHAEL PROF DR MED (DE)
**Classification:**
**- international:** ***C12Q1/68;*** **C12Q1/68;** (IPC1-7): C12Q1/68; G01N33/68
**- european:** C12Q1/68M6B
**Application number:** DE19971036691 19970822
**Priority number(s):** DE19971036691 19970822

**Also published as:**
WO9910528 (A1)
EP1007740 (A1)
US7056660 (B1)
EP1007740 (A0)
CA2301962 (A1)

Report a data error here

Abstract of **DE19736691**

Characterising and identifying disseminated and metastatic cancer cells using RNA and DNA comprises examining a body fluid sample for at least one cancer-specific gene (I) and at least one cancer-associated gene (II). An Independent claim is also included for agents used in the new process, preferably in test and/or diagnostic kits.